Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (11-20 of 434) with videos related to

Pageof 44
Sort By:
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of MagrolimabFadi Haddad, Naval Daver
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2018
Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge SwordBetul Oran, Naval Daver
The Lancet. Oncology|November 10, 2015
Sorafenib and novel multikinase inhibitors in AMLNaval Daver, Marina Konopleva
Hematology (Amsterdam, Netherlands)|April 18, 2012
Molecular targeted therapy in acute myeloid leukemiaNaval Daver, Jorge Cortes
Leukemia & Lymphoma|June 11, 2014
Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosisNaval Daver, Srdan Verstovsek
Current Hematologic Malignancy Reports|March 30, 2013
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodiesNaval Daver, Susan O'Brien
Blood|June 11, 2016
Enhancing cytotoxicity of immunotoxins in AMLNaval Daver, Farhad Ravandi
The American Journal of Managed Care|August 23, 2018
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathwayLindsey Lyle, Naval Daver
Best Practice & Research. Clinical Haematology|June 18, 2019
AML: The future is now or was it yesterday?Naval Daver, Eytan Stein
Blood|September 10, 2016
Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALLNaval Daver, Marina Konopleva
Pageof 44

Showing results (11-20 of 434) with videos related to

Sort By:
Pageof 44
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of MagrolimabFadi Haddad, Naval Daver
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2018
Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge SwordBetul Oran, Naval Daver
The Lancet. Oncology|November 10, 2015
Sorafenib and novel multikinase inhibitors in AMLNaval Daver, Marina Konopleva
Hematology (Amsterdam, Netherlands)|April 18, 2012
Molecular targeted therapy in acute myeloid leukemiaNaval Daver, Jorge Cortes
Leukemia & Lymphoma|June 11, 2014
Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosisNaval Daver, Srdan Verstovsek
Current Hematologic Malignancy Reports|March 30, 2013
Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodiesNaval Daver, Susan O'Brien
Blood|June 11, 2016
Enhancing cytotoxicity of immunotoxins in AMLNaval Daver, Farhad Ravandi
The American Journal of Managed Care|August 23, 2018
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathwayLindsey Lyle, Naval Daver
Best Practice & Research. Clinical Haematology|June 18, 2019
AML: The future is now or was it yesterday?Naval Daver, Eytan Stein
Blood|September 10, 2016
Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALLNaval Daver, Marina Konopleva
Pageof 44